Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 23, 2004. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Purchase Date: September 22, 2004.
- Purchase Price: 1,192.5 pence per share.
- Treasury Holdings Post-Purchase: 45,923,000 shares.
- Shares in Issue (excluding Treasury): 5,889,078,094 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 500,000 shares to be held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 500,000 share repurchase (500,000 shares x 1,192.5 pence).
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the full Annual General Meeting minutes from May 17, 2004, to understand the scope of the share buyback authority.
- Note that this filing does not contain quarterly or annual financial performance data.